MED — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-03

• Certain information in this report contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Act”). Forward-looking …

• The following discussion should be read in conjunction with the unaudited condensed consolidated financial statements and related notes appearing elsewhere herein.

• Medifast, Inc. (“Medifast,” the “Company,” “we” or “us”) is the health and wellness company known for its science-backed, comprehensive metabolic health system. In October 2025, Medifast announced its strategic transformation, unveiling its focus on holistic metabolic health. The Company started 202…

• loss to address the broader metabolic health challenges impacting more than 90% of U.S. adults today. Medifast’s approach focuses on addressing the root cause of metabolic dysfunction. This strategic shift targets a larger and what is believed to be a more sustainable market, focusing on a long-term…

• This growth strategy will initially be focused on improving coach productivity and expanding our coach network. We operate a well-capitalized business with a powerful lifestyle solution and a business model that has impacted over 3 million lives and, for the quarter ended June 30, 2026, had a networ…

Text removed vs the prior filing · source: 10-Q · 2026-05-04

• Item 3 – Quantitative and Qualitative Disclosures about Market Risk

• Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds

• The accompanying notes are an integral part of these condensed consolidated financial statements.

• CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)

• The accompanying notes are an integral part of these condensed consolidated financial statements.

Text added vs the prior filing · source: 10-Q · 2026-08-03

• (U.S. dollars in thousands, except per share amounts & dividend data)

• Unrealized net losses on investment securities(22)(60)(222)(1)

• Net cash flow provided by (used in) investing activities(18,366)11,303

• Increase (decrease) in cash and cash equivalents(17,393)10,766

• Cash and cash equivalents - beginning of the period89,30390,928

Text removed vs the prior filing · source: 10-Q · 2026-05-04

• Cash and cash equivalents - beginning of the period89,303 90,928

• Dividends included in accounts payable and accrued expenses$206 $453

• months ended March 31, 2025, an effective rate of 246.8%. The decrease in the effective tax rate was primarily driven by the increased loss incurred in the March 31, 2026 period and the valuation allowance on the net deferred tax assets. The Company will continue to assess the realizability of its d…

• The Company was in a loss position for the three months ended March 31, 2026 and 2025, and as such all awards were anti-dilutive. If the Company was not in a loss position, the calculation of diluted EPS would have included the effect of dilutive common stock equivalents of 188 thousand and 57 thous…

• The total fair value of market and performance-based share awards issued during the three months ended March 31, 2026 was $0.2 million. The Company withheld approximately 8 thousand shares for the quarter ended March 31, 2026 to cover minimum tax liability withholding obligations upon the issuance o…

Text added vs the prior filing · source: 10-Q · 2026-08-03

• (U.S. dollars in thousands, except per share amounts & dividend data)

• Unrealized net losses on investment securities(22)(60)(222)(1)

• Net cash flow provided by (used in) investing activities(18,366)11,303

• Increase (decrease) in cash and cash equivalents(17,393)10,766

• Cash and cash equivalents - beginning of the period89,30390,928

Text removed vs the prior filing · source: 10-Q · 2026-05-04

• Cash and cash equivalents - beginning of the period89,303 90,928

• Dividends included in accounts payable and accrued expenses$206 $453

• months ended March 31, 2025, an effective rate of 246.8%. The decrease in the effective tax rate was primarily driven by the increased loss incurred in the March 31, 2026 period and the valuation allowance on the net deferred tax assets. The Company will continue to assess the realizability of its d…

• The Company was in a loss position for the three months ended March 31, 2026 and 2025, and as such all awards were anti-dilutive. If the Company was not in a loss position, the calculation of diluted EPS would have included the effect of dilutive common stock equivalents of 188 thousand and 57 thous…

• The total fair value of market and performance-based share awards issued during the three months ended March 31, 2026 was $0.2 million. The Company withheld approximately 8 thousand shares for the quarter ended March 31, 2026 to cover minimum tax liability withholding obligations upon the issuance o…

Text added vs the prior filing · source: 10-Q · 2026-08-03

• (U.S. dollars in thousands, except per share amounts & dividend data)

• Unrealized net losses on investment securities(22)(60)(222)(1)

• Net cash flow provided by (used in) investing activities(18,366)11,303

• Increase (decrease) in cash and cash equivalents(17,393)10,766

• Cash and cash equivalents - beginning of the period89,30390,928

Text removed vs the prior filing · source: 10-Q · 2026-05-04

• Cash and cash equivalents - beginning of the period89,303 90,928

• Dividends included in accounts payable and accrued expenses$206 $453

• months ended March 31, 2025, an effective rate of 246.8%. The decrease in the effective tax rate was primarily driven by the increased loss incurred in the March 31, 2026 period and the valuation allowance on the net deferred tax assets. The Company will continue to assess the realizability of its d…

• The Company was in a loss position for the three months ended March 31, 2026 and 2025, and as such all awards were anti-dilutive. If the Company was not in a loss position, the calculation of diluted EPS would have included the effect of dilutive common stock equivalents of 188 thousand and 57 thous…

• The total fair value of market and performance-based share awards issued during the three months ended March 31, 2026 was $0.2 million. The Company withheld approximately 8 thousand shares for the quarter ended March 31, 2026 to cover minimum tax liability withholding obligations upon the issuance o…

Text added vs the prior filing · source: 10-Q · 2026-08-03

• (U.S. dollars in thousands, except per share amounts & dividend data)

• Unrealized net losses on investment securities(22)(60)(222)(1)

• Net cash flow provided by (used in) investing activities(18,366)11,303

• Increase (decrease) in cash and cash equivalents(17,393)10,766

• Cash and cash equivalents - beginning of the period89,30390,928

Text removed vs the prior filing · source: 10-Q · 2026-05-04

• Cash and cash equivalents - beginning of the period89,303 90,928

• Dividends included in accounts payable and accrued expenses$206 $453

• months ended March 31, 2025, an effective rate of 246.8%. The decrease in the effective tax rate was primarily driven by the increased loss incurred in the March 31, 2026 period and the valuation allowance on the net deferred tax assets. The Company will continue to assess the realizability of its d…

• The Company was in a loss position for the three months ended March 31, 2026 and 2025, and as such all awards were anti-dilutive. If the Company was not in a loss position, the calculation of diluted EPS would have included the effect of dilutive common stock equivalents of 188 thousand and 57 thous…

• The total fair value of market and performance-based share awards issued during the three months ended March 31, 2026 was $0.2 million. The Company withheld approximately 8 thousand shares for the quarter ended March 31, 2026 to cover minimum tax liability withholding obligations upon the issuance o…

Text added vs the prior filing · source: 10-Q · 2026-08-03

• (U.S. dollars in thousands, except per share amounts & dividend data)

• The accompanying notes are an integral part of these condensed consolidated financial statements.

• CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)

• Unrealized net losses on investment securities(22)(60)(222)(1)

• The accompanying notes are an integral part of these condensed consolidated financial statements.

Text removed vs the prior filing · source: 10-Q · 2026-05-04

• During the three months ended March 31, 2026, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.